Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wannee Kantasiripitak

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Clinical Pharmacology|January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseasesWannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Frontiers in Pharmacology|May 28, 2020
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?Wannee Kantasiripitak, Ruth Van Daele, Matthias Gijsen, et al.
Inflammatory Bowel Diseases|August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative ColitisErwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology|February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 16, 2022
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseasesWannee Kantasiripitak, An Outtier, Sebastian G Wicha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
British Journal of Clinical Pharmacology|January 15, 2026
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisFloris Fauchet, Anna Largajolli, Petra M Jauslin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Clinical Pharmacology|January 17, 2022
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseasesWannee Kantasiripitak, Zhigang Wang, Isabel Spriet, et al.
Frontiers in Pharmacology|May 28, 2020
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?Wannee Kantasiripitak, Ruth Van Daele, Matthias Gijsen, et al.
Inflammatory Bowel Diseases|August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative ColitisErwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
British Journal of Clinical Pharmacology|February 19, 2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseasesWannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, et al.
Journal of Crohn'S & Colitis|January 20, 2023
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel DiseasesWannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 16, 2022
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseasesWannee Kantasiripitak, An Outtier, Sebastian G Wicha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
British Journal of Clinical Pharmacology|January 15, 2026
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisFloris Fauchet, Anna Largajolli, Petra M Jauslin, et al.
Pageof 1